Human papillomaviruses is a diverse group of DNA-based viruses that infect the mucous and skin membranes of humans and various animals. More than 100 different types of human papillomavirus have been characterized. Increasing prevalence of various cancers caused by human papillomavirus is expected to drive the market during the forecast period. According to the Centers for Disease Control and Prevention (CDC), human papillomavirus is the most common sexually transmitted infection in the U.S. Over 60% of penile cancers, 70% of vulvar and vaginal cancers, and 90% of anal and cervical cancers are caused due to human papillomavirus infection.
Merck & Co., In. and GSK- Notable Market Players in HPV Vaccines Market
The HPV Vaccines market majorly consists of the players such as Merck & Co. In.; GSK, Serum Institute of India; Walvax Biotechnologies; Innovax; Vaccitech; Innovio Pharmaceuticals; Chengdu Institute of Biological Products Co., Ltd.; Sanofi; R-Pharm; Shanghai Bowei; and Bioleaders. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized strategies such as product launches, expansions, and product upgradations for the growth of their organizations. The companies have adopted several inorganic and organic strategies to accelerate their growth and improve their market position.
Below is the list of the growth strategies done by the players operating in the HPV Vaccines market:
| Year | News |
| May-22 | China’s National Medical Products Administration (NMPA) has approved GlaxoSmithKline’s (GSK) two-dose vaccine schedule, Cervarix, in girls between nine to 14 years to prevent cervical cancer. Cervarix is a recombinant, non-infectious, AS04-adjuvanted HPV bivalent (types 16, 18) vaccine. |
| May-22 | Serum Institute of India is developing a tetravalent HPV vaccine which includes L1 VLPs of serotypes 6,11,16,18, which is expected to give a coverage of approximately 90% against papilloma virus prevalent in the developing world. The vaccine is currently under development and will be available in the near future. |
| Mar-22 | China’s NMPA has given a green light for Walvax Biotechnology Co. Ltd.’s human papillomavirus (HPV) bivalent vaccine to be used against HPV types 16 and 18 to prevent cervical cancer. |
| Nov-21 | Merck announced the successful completion of the acquisition of Acceleron Pharma Inc. |
| Oct-21 | Cecolin, a vaccine against human papillomavirus (HPV), has received prequalification by the World Health Organization (WHO). Cecolin is manufactured by Xiamen Innovax Biotech CO., LTD. (Innovax), a wholly-owned subsidiary of Beijing Wantai Biological Pharmaceutical Co., LTD. (Wantai), and is designed to protect against HPV types 16 and 18, the most common virus types that lead to cervical cancer. |
| Mar-21 | Vaccitech Ltd. announced the dosing of the first patient as part of the HPV001 clinical study. HPV001 is a randomized, placebo-controlled Phase 1/2 clinical trial designed to evaluate the safety and preliminary efficacy of VTP-200, Vaccitech’s immunotherapy for high-risk HPV infection and associated low-grade cervical intraepithelial neoplasia. |
| Mar-19 | 2A Pharma, the Swedish/Danish vaccine company, announced that the company had initiated a phase 1 clinical trial of HPV vaccine candidate HPV L2 vaccine candidate. |
